2021: Top 10 Acquisitions of Chinese small enterprises

2022-05-10 0 By

Source: Appliance Home, without authorization, shall not be reproduced in any form, and can be reproduced 24 hours later.In 2021, mergers and acquisitions in the domestic medical industry continue to be active, and the mergers and acquisitions transactions in the first half of the year alone have exceeded the total of the whole year of 2020.The continuous influx of capital adds to the rapid advancement of technological innovation. Appliance Home summarizes the top ten medical mergers and acquisitions in 2021 in China, among which the top three are in the field of in vitro diagnostics!Mindray topped the list in terms of value, while Mindray was listed twice as an acquirer!Let’s take a look back.On September 22, 2021, Mindray Medical announced that it has completed the acquisition of 100% equity interest in HyTest Invest Oy and its subsidiaries in Finland for a price of €532 million (approximately RMB4.035 billion).At this point, sea peptide biology became a mindray medical wholly-owned subsidiary.The acquisition is mindray’s largest ever.Peptide sea creatures, founded in 1994, is one of the world’s top professional in vitro diagnostic upstream raw materials suppliers, the cardiac markers, tumor markers, infectious diseases, inflammation, blood clotting, and other fields have wide distribution, in cardiovascular markers detection, virus detection, and pet raw materials such as the market has competitive advantage in the world, currently has more than 2000 customers,Almost all in vitro diagnostics companies worldwide.The acquisition can complement mindray medical’s shortcomings in in vitro diagnosis raw materials. It can obtain its advanced technology and patents, strengthen the self-research and self-production capacity of core raw materials, and enhance the competitiveness of its own in vitro diagnosis.It can also ensure the safety of the supply chain and avoid being “stuck in the neck”.In addition, Mindray medical also has access to more than 2,000 customers of Sea Peptide biology and a worldwide sales network to further expand overseas markets.On May 13, Shengxiang Biology announced that it would purchase 18.63% shares of Kehua Biology held by Zhuhai Baolian Asset Management Co., Ltd. by agreement at a transaction price of 1.95 billion yuan.Kehua Biology is an in vitro diagnostic company with rich production experience and complete medical diagnostic products.Headquartered in Shanghai, the company has r&d and production bases in Italy, Shenzhen, Xi ‘an, Suzhou and other countries and regions.In July 2004, it was listed on shenzhen Stock Exchange board.Kehua has created two r&d technology platforms for clinical in vitro diagnostic reagents and automatic detection and analysis instruments, realizing the “serialization” and “integration” of diagnostic reagents and instruments.Its products focus on immunodiagnostics, biochemical diagnostics, molecular diagnostics three fields, with more than 260 reagents and instruments approved by NMPA, more than 80 CE certification, some products have also obtained the certification of the United States, South Korea and other countries.At the same time, its Italian subsidiary TGS owns more than 80 CE products.Sungxiang bio, which was listed on the BOARD in August last year, has become the “growth king” in the IVD sector due to the development opportunities brought by the COVID-19 pandemic.Taking advantage of the development opportunities brought by the epidemic, Shengxiang Biological focus on new business development.The acquisition is a strong combination of technology platforms, product lines, channels and markets.It is conducive to further improve the disease solutions of both parties and the full-scene system solutions, and to build a more perfect new ecology of universal and full-scene application of in vitro diagnosis.In addition, due to the existing competition between the two companies, Shengxiang Bio promises to solve the competition problem within 3 years after the signing of the agreement.On September 3, 2021, Jiuqiang Biotechnology announced that the company publicly delisted 30% of Maixin Biotechnology, which was held by Sinopharmics, at a delisting price of 948 million yuan.The deal will increase the company’s stake in The company’s holding subsidiary, which specializes in immunohistochemical diagnostics.On August 3, 2021, China National Pharmaceutical Investment Co., Ltd. listed 30% of its shares in Fuzhou Maixin Biotechnology Development Co., Ltd. on Beijing Equity Exchange at the listing price of 947.5 million yuan.The listing price is 122.5 million yuan, an increase of 14.85%, compared with 825 million yuan when Sinophem and Jiuqiang (300406.SZ) jointly acquired Maixin last year.After the completion of this transaction, Jiuqiang biological business will further cover the clinical diagnostic field of tumor cell screening and post-surgical tumor tissue section, expand the product line of pathological diagnostic reagents and instruments, improve the technology research and development capabilities and marketing network layout, and consolidate the listed company’s leading position in the in vitro diagnostic industry.At the same time, the equity transfer of Maixin is also the rapid strengthening of Jiuqiang after Sinopac’s ownership, making jiuqiang become the only IVD platform of Sinopac.On October 4, 2021, Minimally Invasive Healthcare announced that it has acquired wholly-owned Hemovent GmbH, a German company, for an aggregate price of up to 123 million Euros.Hemovent, inc., founded in 2013, is a medical device company specializing in innovative extracorporeal life support systems with innovative ECMO product technologies.The company’s main product, extracorporeal membrane oxygenation system (ECMO) MOBYBOXSystem, has been CE certified and is the world’s first ECMO system integrating blood pump and membrane lung.After this acquisition, the era of domestic lack of independent high-end ECMO will end.On June 27, 2021, New Oxygen, a US-listed company, announced that it has entered into a definitive agreement with Wuhan Qizhi Laser Technology Co., Ltd. and its shareholder Wuhan Zeqi Technology Co., Ltd. to acquire 84.49% of its shares at a total price of 791 million yuan. The transaction is expected to take place in the third quarter of 2021.New Oxygen Technology Co., Ltd. was founded in March 2013, headquartered in Beijing, China, and listed on NASDAQ in 2019.Its business model has three parts: content and distribution through China’s major social media networks and target media platforms;Social communities characterized by user-generated content and signatures;Online booking of medical cosmetology services.Qizhi Laser, founded in 2001, is the largest high-tech enterprise in China, mainly engaged in the production and operation of laser, bright light medical and beauty equipment.Mainly engaged in laser and other photoelectric medical and beauty equipment research and development, production, sales and agent, independently developed and designed a number of laser, photoelectric medical and beauty equipment.Such as “neodymium doped yttrium aluminum garnet laser treatment machine”, “semiconductor laser hair removal instrument”, “laser treatment machine”, “laser/intense pulse light (commonly known as photon skin rejuvenation) treatment system” and so on.The acquisition will expand New Oxygen’s network of institutions and enhance customer service performance experience.At the same time, it will be an important model for New Oxygen Exploration to partner with more device and drug manufacturers to implement its growth strategy.In August 2021, Zhende Medical Announced that Xuchang Zhende, a wholly-owned subsidiary of the company, planned to acquire 100% equity of Shanghai Asia Australia Medical Health Products Co., LTD and 100% equity of Santerui (Nantong) Medical Materials Co., LTD in cash, with the transfer price of RMB 400 million and RMB 111.7 million respectively.Shanghai Asia Australia is mainly engaged in the production, development and sales of central venous indwelling and wound care solutions (modern wound care products) as the core products.Santerui mainly provides production support and sterilization services for Shanghai Asia and Australia.The business of Shanghai Asia and Australia and Santri is highly coordinated with the business of the company.The target products are mainly sold abroad, among which the overseas sales of Shanghai Asia Australia in 2020 account for 85% of the total sales.According to the strategic development plan of Zhende Medical, this acquisition will further enrich and optimize the company’s core product line (especially in the field of modern wound care and sensory control products), expand product sales channels, expand business scale and enhance the company’s core competitiveness in the market.In October 2021, Qiming Medical announced that it had signed an agreement with Nuocheng Medical to acquire 100% equity and corresponding rights and interests of Nuocheng Medical for a consideration of no more than RMB 493 million, and to make conditional payments in installments based on the completion of agreed milestones.Through the acquisition, Qiming Medical will acquire the Liwen RF radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy (HCM).Qiming Medical, founded in 2009, is a comprehensive platform for innovative devices of structural heart disease. In 2017, its self-developed interventional valve (TAVR) product was approved for listing, and later listed on the main board of Hong Kong Stock Exchange in 2019, becoming the first one among Chinese manufacturers of interventional valve products to be listed.Nuocheng Medical Was founded in 2017 and incubated by Denuo Medical Group. It is a high-tech enterprise focusing on the research and development of hypertrophic cardiomyopathy treatment equipment.The system for cardiac biopsy and ablation of hypertrophic cardiomyopathy has entered the stage of clinical trial.The acquisition will enhance the innovation of Qiming’s medical product pipeline and strengthen its competitive advantage in structural cardiology by leveraging commercialized synergies.In June 3, 2021, Sanyou medical announced that it plans to use its own funds 343 million yuan to buy 49.8769% of shuimu Tianpeng equity.After the completion of the transaction, the company holds 51.8154% of the latter’s equity, shuimu Tianpeng will become the company’s holding subsidiary.Shuimu Tianpeng focuses on the research and development, production and sales of ultrasonic surgical equipment and consumables, and is the leader of ultrasonic energy surgical tools in China.The main products are ultrasonic bone dynamic system (also known as “ultrasonic bone knife”), ultrasonic suction system and ultrasonic hemostatic knife system, involving orthopedics, spine surgery, sixth surgery, plastic surgery, hand and foot surgery, hepatobiliary surgery and many other medical treatment fields.In the field of ultrasonic surgical instruments has more than 10 years of research and development and industrialization experience, products have entered more than 20 provinces and cities of the third grade a hospital.This acquisition represents the gradual expansion of sanyou medical’s business boundaries in the process of business development, from focusing on the research and development of orthopedic implant solutions to focusing on the provision of surgical solutions.It will further enhance its comprehensive strength, enrich its product portfolio, and give play to the synergy between active products and the company’s main business.On October 29, 2021, Minimally Invasive Medical announced the acquisition of 38.33% equity of Argus Medical Technology Co., Ltd. at a transaction consideration of 372 million yuan.In addition to the $372 million to be paid, if Argus can complete the corresponding RESEARCH and development process and production upgrades, its existing shareholders may request a further 31.55% interest in The acquisition of The $268 million from December 31, 2022 to June 30, 2024.In the future, Minimally Invasive medical will be solely responsible for the marketing and application of Argus products.Founded in 2016, Argus Medical designs, develops and markets solutions for intravascular optical interferometric diagnostic layer imaging systems (OCT).This acquisition represents an important position for Minimally Invasive care in the field of total treatment solutions for coronary heart disease. It will further improve its integrated precision care solution in the pan-vascular field and promote the market expansion of OCT systems and their disposable imaging catheter without flushing.On May 11, 2021, Yuyue Medical announced that it intends to acquire 50.993% of the equity held by zhejiang Kelite’s 7 shareholders, and sign an equity transfer agreement with the trading party, with the transaction amount of about 366 million YUAN.Founded in 2010, Kellett is committed to the development, production and marketing of portable medical monitoring systems based on advanced biosensor technology, including dynamic blood glucose monitoring (CGM), blood gas and electrolytes, and other POCT instant testing products, and provides comprehensive, effective and affordable diabetes management solutions.To be the industry’s leading technology innovator and leader.Diabetes and POCT business is one of the three important tracks for the future layout of Yuyue Medical.This acquisition is a combination of two strong.On the one hand, Kelit’s CGM business can rely on the former’s large-scale, intelligent and lean production capacity, share BGM sales resources, software development resources and user operation capabilities, and realize the coordination of RESEARCH and development, production, sales and user service.At the same time, it is also the complete business layout of Yuyue Medical in the diabetes circuit to ensure the long-term and stable growth of its overall performance.